Your search for osteoporosis returned 8 results

Despite initial recognition of opioid-induced androgen deficiency (OPIAD) as a possible consequence of opioid use more than four decades ago, few studies have systematically investigated hormonal changes induced by long-term opioid administration.

Treatment with Prolia (denosumab) or bisphosphonates was associated with a low incidence rate of potential osteonecrosis of the jaw among postmenopausal women with osteoporosis, according to data presented by Fei Xue, MD, Center for Observational Research, Amgen Inc, at the 2015 ACR/ARHP Annual Meeting.

Higher levels of sodium intake are associated with a lower risk of hip fractures among postmenopausal women, but adherence to sodium-intake recommendations for cardiovascular health does not affect bone mineral density (BMD), according to findings from the Women’s Health Initiative (WHI) reported at the 2015 ACR/ARHP Annual Meeting.

Marvel J. Hammer, RN, CPC, CCS-P, ACS-PM, CPCO, of MJH Consulting, Denver, Colorado provided PAINWeek attendees a detailed overview of the differences between ICD-9-CM and ICD-10-CM codes for many diagnoses currently encountered in pain management and a list of steps to ease the transition to ICD-10-CM.

Significant increases in bone mineral density (BMD) were observed after 12 months of treatment with denosumab vs. placebo in patients with rheumatoid arthritis (RA) regardless of glucocorticoid use, according to a study presented at the 2013 ACR/ARHP Annual Meeting.

Anatomic variability in women predisposes them to specific musculoskeletal conditions, which differ during life stages. “There are important differences between the sexes for many clinical pain disorders which may be explained, at least in part, by hormonal mechanisms,” said Colleen M. Fitzgerald, MD, MS at PAINWeek 2013.

Adult patients with acute lymphocytic leukemia (ALL) and lymphoblastic lymphoma (LL) treated with the Hyper-CVAD regimen are at very high risk for rapid bone loss from the high-dose corticosteroid early in their treatment, the first study to show such a loss concluded during at the 53rd American Society of Hematology Annual Meeting and Exposition.

Exemestane, an aromatase inhibitor, can be considered a new option for primary prevention of breast cancer in postmenopausal women, results of a randomized, placebo-controlled trial reported upon during the American Society of Clinical Oncology’s 2011 Annual Meeting and published online in The New England Journal of Medicine have found.